Alison L. Hannah

Alison L. Hannah

Company: CytomX Therapeutics

Job title: Senior Vice President and Chief Medical Officer


Clinical Development of Praluzatamab Ravtansine (CX-2009), a Conditionally Activated Probody Drug Conjugate (PDC) Targeted Against CD166 (ALCAM) in Patients with Advanced Breast Cancer 10:00 am

• Probody drug conjugates are a new class of conditionally activated antibody prodrugs that remain largely inactive until the substrate linker is cleaved by upregulated protease activity in the tumor microenvironment • Praluzatamab ravtansine is targeted against CD166 (ALCAM), a cell surface receptor that is widely expressed on normal and malignant cells, including hormone receptor…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.